Treatment of onychomycosis in the diabetic patient population

Journal of Diabetes and its Complications

Volumn 17, Issue 2, 2003, Pages 98-104

  Robbins, Jeffrey M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antifungals; Ciclopirox; Diabetes; Onychomycosis; Therapy; Topical

Indexed keywords

ANTIFUNGAL AGENT; ASTEMIZOLE; CAFFEINE; CICLOPIROXOLAMINE; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; NICOTINIC ACID; RIFAMPICIN; TERBINAFINE; TERFENADINE;

ARTICLE; BURNING SENSATION; CLINICAL TRIAL; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; ERYTHEMA; HEADACHE; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; LIVER INJURY; MORBIDITY; ONYCHOMYCOSIS; PAIN; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SKIN TINGLING; SUPERINFECTION; TOPICAL TREATMENT; VERTIGO; WOUND HEALING IMPAIRMENT;

ANTIBIOTICS, ANTIFUNGAL; DIABETES COMPLICATIONS; HUMANS; ONYCHOMYCOSIS;

EID: 0037373970     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(02)00199-X     Document Type: Article

References (52)

1. Albreski D.A., Gross E.G. The safety of itraconazole in the diabetic population. Journal of the American Podiatric Medical Association. 89:1999;339-345.
2. Anon. (2000). Ciclopirox (Penlac) nail lacquer for onychomycosis. Medical Letters on Drugs and Therapeutics, 42, 51-52.
3. Boyko, W. L., Doyle, J. J., Ryu, S., & Gause, D. (1999, May). Onychomycosis and its impact on secondary infection development in the diabetic population [Abstract]. Presented at the 4th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA.
4. Breckenridge A. Clinical significance of interactions with antifungal agents. British Journal of Dermatology. 126(Suppl. 39):1992;19-22.
5. Carstens J., Wendelboe P., Søgaard H., Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Dermato-Venereologica. 74:1994;391-392.
6. Ceschin-Roques C.G., Hanel H., Pruja-Bougaret S.M., Luc J., Vandermander J., Michel G. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacology. 4:1991;89-94.
7. Chien R.-N., Yang L.-J., Lin P.-Y., Liaw Y.-F. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology. 25:1997;103-107.
8. Del Rosso J.Q. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. Journal of the American Osteopathic Association. 97:1997;339-346.
9. Doyle, J. J., Boyko, W., Ryu, S., & Gause, D. (2000). Onychomycosis among diabetic patients: prevalence and impact of nonfungal foot infections [Abstract]. Presented at the 60th Scientific Sessions of the American Diabetes Association, San Antonio, TX, June 11, 2000.
10. Drake L., Babel D., Stewart D.M., Rich P., Ling M.R., Breneman D., Scher R.K., Martin A.G., Pariser D.M., Pariser R.J., Ellis C.N., Kang S., Katz H.I., McDonald C.J., Muglia J., Savin R.C., Webster G., Elewski B.E., Leyden J.J., Bucko A.D., Tschen E.H., Hanifin J.M., Morman M.R., Shupack J.L., Greer D.L. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. Journal of the American Academy of Dermatology. 38:1998;S87-S94.
11. Drake L.A., Patrick D.L., Fleckman P., André J., Baran R., Haneke E., Sapède C., Tosti A. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. Journal of the American Academy of Dermatology. 41:1999;189-196.
12. Elewski B.E. Diagnostic techniques for confirming onychomycosis. Journal of the American Academy of Dermatology. 35(3 Pt 2):1996;S6-S9.
13. Elewski B.E. The effect of toenail onychomycosis on patient quality of life. International Journal of Dermatology. 36:1997;754-756.
14. Elewski B.E. Onychomycosis: pathogenesis, diagnosis, and management. Clinical Microbiology Reviews. 11:1998;415-429.
15. Elewski B.E., Scher R.K., Aly R.et al. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis. 59:1997;217-220.
16. Evans S.L., Nixon B.P., Lee I., Yee D., Mooradian A.D. The prevalence and nature of podiatric problems in elderly diabetic patients. Journal of the American Geriatrics Society. 39:1991;241-245.
17. FDA Public Health Advisory. (2002). Food and Drug Administration Website. Available at: http://www.fda.gov/cder/drug/advisory/sporanox-lamisil/advisory.htm . Accessed January 18, 2002.
18. Gupta A.K. Ciclopirox nail lacquer topical solution 8%. Skin Therapy Letter. 6:2000;1-5.
19. Gupta A.K., Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. Journal of the American Academy of Dermatology. 43(Suppl. 4):2000;S96-S102.
20. Gupta A.K., Einarson T.R., Summerbell R.C., Shear N.H. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs. 55:1998;645-674.
21. Gupta A.K., Fleckman P., Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. Journal of the American Academy of Dermatology. 43:2000;S70-S80.
22. Gupta A.K., Humke S. The prevalence and management of onychomycosis in diabetic patients. European Journal of Dermatology. 10:2000;379-384.
23. Gupta A.K., Joseph W.S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. Journal of the American Podiatric Medical Association. 90:2000;495-501.
24. Gupta A.K., Konnikov N., MacDonald P., Rich P., Rodger N.W., Edmonds M.W., McManus R., Summerbell R.C. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicenter survey. British Journal of Dermatology. 139:1998;665-671.
25. Gupta A.K., Malkin K.F. Ciclopirox nail lacquer and podiatric practice. Journal of the American Podiatric Medical Association. 90:2000;502-507.
26. Haneke E., Abeck D., Ring J. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Mycoses. 41:1998;521-527.
27. Havu V., Brandt H., Heikkilä H., Hollmen A., Oksman R., Rantanen T., Saari S., Stubb S., Turjanmaa K., Piepponen T. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. British Journal of Dermatology. 136:1997;230-234.
28. Hofmann H., Brautigam M., Weidinger G., Zaun H. Treatment of toenail onychomycosis. A randomized double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Archives of Dermatology. 131:1995;919-922.
29. Karchmer A.W., Gibbons G.W. Foot infections in diabetes: evaluation and management. Current Clinical Topics in Infectious Diseases. 14:1994;1-22.
30. Katz H.I. Drug interactions of the newer oral antifungal agents. British Journal of Dermatology. 141(Suppl. 56):1999;26-32.
31. Katz H.I., Gupta A.K. Oral antifungal drug interactions. Dermatologic Clinics. 15:1997;535-544.
32. Kuokkanen K., Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. Journal of Dermatology. 3:1993;115-117.
33. Lawry M.A., Haneke E., Strobeck K., Matrin S., Zimmer B., Romano P. Methods for diagnosing onychomycosis. A comparative study and review of the literature. Archives of Dermatology. 136:2000;1112-1116.
34. Levy L.A. Epidemiology of onychomycosis in special-risk populations. Journal of the American Podiatric Medical Association. 87:1997;546-550.
35. Lo A.C.Y., Lui S.-L., Lo W.-K., Chan D.T.M., Cheng I.K.P. The interaction of terbinafine and cyclosporine A in renal transplant patients. British Journal of Clinical Pharmacology. 43:1996;340-341.
36. Lubeck D.P., Patrick D.L., McNulty P., Fifer S.K., Birnbaum J. Quality of life of persons with onychomycosis. Quality of Life Research. 2:1993;341-348.
37. Lugo-Somolinos A., Sánchez J.L. Prevalence of dermatophytosis in patients with diabetes. Journal of the American Academy of Dermatology. 26:1992;408-410.
38. May 2001 safety-related drug labeling changes. (2002). Available at: http://www.fda.gov/medwatch/SAFETY/2001/May01.htm#sporan . Accessed January 18, 2002.
39. O'Sullivan D.P. Terbinafine: tolerability in general medical practice. British Journal of Dermatology. 141(Suppl. 56):1999;21-25.
40. Penk A., Pittrow L. Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. Mycoses. 42(Suppl. 2):1999;97-100.
41. Perez M.I., Kohn S.R. Cutaneous manifestations of diabetes mellitus. Journal of the American Academy of Dermatology. 30:1994;519-531.
42. Perfect J.R., Lindsay M.H., Drew R.H. Adverse drug reactions to systemic antifungals. Prevention and management. Drug Safety. 7:1992;323-363.
43. Pollack R., Billstein S.A. Safety of oral terbinafine for toenail onychomycosis. Journal of the American Podiatric Medical Association. 87:1997;565-570.
44. Ramsey S.D., Newton K., Blough D., McCulloch D.K., Sandhu N., Wagner E.H. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics. 16:1999;285-295.
45. Rich P. Special patient populations: onychomycosis in the diabetic patient. Journal of the American Academy of Dermatology. 35:1996;S10-S12. Suppl.
46. Rich P. Onychomycosis and tinea pedis in patients with diabetes. Journal of the American Academy of Dermatology. 43(Suppl. 5):2000;S130-S134.
47. Rich P., Hare A. Onychomycosis in a special patient population: focus on the diabetic. International Journal of Dermatology. 38(Suppl. 2):1999;17-19.
48. Scher R.K., Breneman D., Rich P., Savin R.C., Feingold D.S., Konnikov N., Shupack J.L., Pinnell S., Levine N., Lowe N.J., Aly R., Odom R.B., Greer D.L., Morman M.R., Bucko A.D., Tschen E.H., Elewski B.E., Smith E.B. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. Journal of the American Academy of Dermatology. 38:1998;S77-S86.
49. Seebacher C., Nietsch K.-H., Ulbricht H.M. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer 8% solution for the treatment of onychomycosis in diabetic patients. Cutis. 68:2001;17-22.
50. Tom C.M., Kane M.P. Management of toenail onychomycosis. American Journal of Health System Pharmacy. 56:1999;865-871.
51. Tosti A., Piraccini B.M., Stinchi C., Venturo N., Bardazzi F., Colombo M.D. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Journal of the American Academy of Dermatology. 34:1996;595-600.
52. Verspeelt J., Marynissen G., Gupta A.K., De Doncker P. Safety of itraconazole in diabetic patients. Dermatology. 198:1999;382-384.